Everyday life for the more than 46 million people around the world who suffer from type 1 diabetes could become much easier and safer.

Researchers from the University of Copenhagen and biotech firm Gubra have developed a new insulin molecule that, in the future, will ensure that diabetics receive just the right amount of insulin.

The insulin on the market today is unable to identify whether a patient with type 1 diabetes needs a small or large effect from the insulin, which lowers blood sugar.

"That is why we have developed the first step towards a kind of insulin that can self-adjust according to a patient's blood sugar level. This has tremendous potential to vastly improve the lives of people with type 1 diabetes," explains Professor Knud J. Jensen, of the University of Copenhagen's Department of Chemistry, one of the researchers behind a new study on this new insulin.

Effective in rats

The researchers behind the study developed a type of insulin with a built-in molecular-binding that can sense how much blood sugar is in the body. As blood sugar rises, the molecule becomes more active and releases more insulin. As blood sugar drops, less is released.

"The molecule constantly releases a small amount of insulin, but varies according to need," says Knud J. Jensen, who continues:

"It will give type 1 diabetes patients a safer and easier treatment. Today, a person with type 1 diabetes must inject themselves with insulin many times throughout the day and frequently monitor their blood sugar level by pricking their finger with a blood glucose meter. This here, allows a person to inject the new insulin molecule less often over the course of a day and thereby think about it less," says Knud J. Jensen.

Although the new 'automated' insulin is a major advance towards better diabetes treatment, it will be a while before the revolutionary insulin becomes a part of diabetics' everyday lives.

"We've tested the insulin molecule on rats and it has proven itself effective. The next step is to develop the molecule so that it works more rapidly and accurately. And finally, to test it in humans -- a process that can take many years. But it is certainly worth pinning one's hopes on," explains Professor Jensen.

Pancreatic disorders and Therapy is now accepting submissions on this topic. A standard EDITORIAL TRACKING SYSTEM is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (www.longdom.org/submissions/pancreatic-disorders-therapy.html ) or forwarded to the Editorial Office at manuscripts@longdom.org

Regards,

Jessica Celina

Managing Editor

Pancreatic disorders and Therapy